<table>
<thead>
<tr>
<th>Title</th>
<th>Use of FDG PET to Evaluate Hyperbaric Oxygen Therapy for Bisphosphonate-Related Osteonecrosis of the Jaw</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Yamazaki, Yutaka; Kitagawa, Yoshimasa; Hata, Hironobu; Abe, Takahiro; Murai, Chika; Shiga, Tohru; Tamaki, Nagarha</td>
</tr>
<tr>
<td>Citation</td>
<td>Clinical Nuclear Medicine, 35(8), 590-591</td>
</tr>
<tr>
<td>Issue Date</td>
<td>2010-08</td>
</tr>
<tr>
<td>Doc URL</td>
<td><a href="http://hdl.handle.net/2115/47876">http://hdl.handle.net/2115/47876</a></td>
</tr>
<tr>
<td>Rights</td>
<td>This is a non-final version of an article published in final form in Clinical Nuclear Medicine 35(8), August 2010, pp 590-591</td>
</tr>
<tr>
<td>Type</td>
<td>article (author version)</td>
</tr>
<tr>
<td>File Information</td>
<td>CNM35-8_590-591.pdf</td>
</tr>
</tbody>
</table>

Hokkaido University Collection of Scholarly and Academic Papers: HUSCAP
Use of FDG-PET to evaluate hyperbaric oxygen therapy for bisphosphonate-related osteonecrosis of the jaw

Yutaka Yamazaki, DDS, PhD,* Yoshimasa Kitagawa, DDS, PhD,*
Hironobu Hata, DDS, PhD,* Takahiro Abe, DDS, PhD,*
Chika Murai, DDS,* Tohru Shiga, MD, PhD,† Nagara Tamaki, MD, PhD†

*Oral Diagnosis and Medicine, Graduate School of Dental Medicine, Hokkaido University
†Nuclear Medicine, Graduate School of Medicine, Hokkaido University

Abbreviated title: FDG-PET to evaluate HBO therapy for BRONJ

* Corresponding author: Yutaka Yamazaki
Oral Diagnosis and Medicine, Graduate School of Dental Medicine, Hokkaido University, Kita-13 Nishi-7, Kita-ku, Sapporo 060-8586, Japan.
Phone/Fax: +81-11-706-4280; E-mail: yutaka8@den.hokudai.ac.jp
Abstract:
An 80-year-old man presented with painful swelling in the mandibular region and fistula with pus discharge that developed after tooth extractions. He had taken oral alendronate sodium hydrate and prednisolone for osteoporosis for five years. The lesion was diagnosed as bisphosphonate-related osteonecrosis of the jaw. FDG-PET revealed a high accumulation of FDG in the right mandibular region. The patient underwent hyperbaric oxygen therapy twenty times. FDG-PET SUVmax drastically decreased from 5.6 to 1.8 after hyperbaric oxygen therapy, paralleling the change in clinical symptoms, while other modalities did not show remarkable changes. This is the first study demonstrating the utility of FDG-PET in monitoring hyperbaric oxygen therapy for bisphosphonate-related osteonecrosis of the jaw.

Key Words: bisphosphonate-related osteonecrosis of the jaw, FDG-PET, hyperbaric oxygen therapy
REFERENCES


Figure Legends

FIGURE 1. An 80-year-old man had a history of oral administration of alendronate for five years. A: Panoramic radiograph before extraction of the lower right first and second molars (black arrows) showed only periodontitis in the whole mandible. B: Panoramic radiograph 4 months after extraction of teeth showed extensive bone destruction (black arrows), consistent with bisphosphonate-related osteonecrosis of the jaw. C: Axial CT showed osteolytic changes and sequestration accompanied by diffuse osteosclerosis (white arrow). D: Axial T1-weighted contrast-enhanced MR showed soft tissue mass of the right mandibular cancellous bone with some contrast enhancement (black arrow).

FIGURE 2. The patient underwent hyperbaric oxygen therapy (HBO) twenty times, resulting in the disappearance of clinical symptoms including pain, swelling and fistula. A (Before HBO): Bone scintigraphy revealed increased RI uptake in the right mandibular region. B (Before HBO): Axial and coronal FDG-PET images showed a high FDG accumulation ($\text{SUVmax} = 5.6$) in the lesion. C (After HBO): Bone scintigraphy did not show remarkable changes compared with the image taken before HBO (A). D (After HBO): FDG-PET revealed normalization of the FDG accumulation ($\text{SUVmax} = 1.8$) consistent with the absence of clinical symptoms. Based on PET evaluation, the patient successfully underwent conservative minor surgery, avoiding continuous resection of the mandible.

The management of patients with bisphosphonate-related osteonecrosis of
the jaw remains extremely difficult and empiric.\textsuperscript{1-3} Although the utility of HBO in the treatment of this condition is currently under investigation,\textsuperscript{4,5} some studies have reported that HBO was helpful in the treatment of bisphosphonate-related osteonecrosis of the jaw.\textsuperscript{5-8} This is the first study to demonstrate the usefulness of FDG-PET in monitoring HBO therapy for bisphosphonate-related osteonecrosis of the jaw.